The Rosen Law Firm, a global investor rights firm, announces that a class action lawsuit has been filed on behalf of purchasers of Celladon Corporation (NASDAQ:CLDN) common stock from July 7, 2014 through June 25, 2015, all dates inclusive. The lawsuit seeks to recover damages for Celladon investors under the federal securities laws.

To join the Celladon class action, go to the firm's website at http://www.rosenlegal.com/cases-660.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or kchan@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, Celladon misstated or failed to disclose adverse information regarding the prospects for MYDICAR—the Company's promising investigational drug for heart failure patients, including that: (1) success in the CUPID1 trial was not indicative of any success in the CUPID2 trial since the CUPID1 trial was extremely small; and (2) the Company's existence was tied to the trial results and defendants were aware of their limitations. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 31, 2015. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the class action and recover your losses, go to the firm's website at http://www.rosenlegal.com/cases-660.html or to discuss your rights or interests regarding this class action, please contact, Phillip Kim, Esq. or Kevin Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com.

The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150702005906/en/

Copyright Business Wire 2010